优降宁盐酸盐 - CAS:306-07-0 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	优降宁盐酸盐促销
英文名称:	Pargyline HCL
别名:	Monoamine Oxidase Eutonyl-ten; N-Methyl-N-propargylbenzylamine hydrochloride; Pargyline;N-benzyl-N-methylprop-2-yn-1-amine;hydrochloride
CAS No:	306-07-0	分子式:	C₁₁H₁₄ClN	分子量:	195.69
CAS No:	306-07-0
分子式:	C₁₁H₁₄ClN
分子量:	195.69
EINEC:	206-175-1
EINEC:	206-175-1

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

P10400 优降宁盐酸盐 ≥98%(HPLC) (psaitong)

相关产品

包装规格：

1g 5g in glass bottle

溶解性：

溶于DMSO(≥30mg/mL)

产品描述：

基本信息

产品编号：	P10400
产品名称：	Pargyline HCL
CAS:	306-07-0	储存条件	粉末	-20℃	四年

分子式：	C11H14ClN		溶于液体	-80℃	两年
分子量	195.69			-20℃	1个月
化学名：	N-Methyl-N-propargylbenzylamine hydrochloride
Solubility (25°C)：
体外:	DMSO	39 mg/mL (199.29mM)
	Water	39 mg/mL (199.29mM)
	Ethanol	39 mg/mL (199.29mM)
体内(现配现用):	1.请依序添加每种溶剂： 10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: ≥ 2.5 mg/mL (12.78mM); Clear solution
	此⽅案可获得 ≥ 2.5 mg/mL (12.78mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50μL Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。
	2.请依序添加每种溶剂： 10% DMSO→90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (12.78 mM); Clear solution
	此⽅案可获得 ≥ 2.5 mg/mL (12.78mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。
	3.请依序添加每种溶剂： 10% DMSO→90% corn oil Solubility: ≥ 2.5 mg/mL (12.78mM); Clear solution
	此⽅案可获得 ≥ 2.5 mg/mL (12.78mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1mL ⼯作液为例，取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中，混合均匀。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	5.1101mL	25.5506mL	51.1012mL
5mM	1.0220mL	5.1101mL	10.2202mL
10mM	0.5110mL	2.5551mL	5.1101mL
50mM	0.1022mL	0.5110mL	1.0220mL

生物活性

产品描述	一种不可逆的单胺氧化酶(MAO)抑制剂。
靶点	MAO-B (Cell-free assay)	MAO-A (Cell-free assay)
靶点	0.5μM(Ki)	13μM(Ki)
体外研究	Pargyline (0.5-2mM; 24-120 hours; LNCaP-LN3 cells) treatment inhibits the proliferation of prostate cancer cells in a time- and dose-dependent manner Pargyline (0.5-2mM; 24-48 hours; LNCaP-LN3 cells) treatment decreases S phase and increases the G1 phase in the cells in a dose-dependent manner Pargyline (0.5mM; 24 hours; LNCaP-LN3 cells) treatment increases the apoptotic cells Pargyline (2mM; 48 hours; LNCaP-LN3 cells) treatment induces an increase of cytochrome c and a decrease of caspase-3 in the cells, but does not lead to a change of BCL-2 expression Cell Proliferation Assay
	Cell Line:	LNCaP-LN3 cells
	Concentration:	0.5mM, 1mM, 1.5mM or 2mM
	Incubation Time:	24 hours, 48 hours, 72 hours, 96 hours or 120 hours
	Result:	Inhibited the proliferation of prostate cancer cells in a time- and dose-dependent manner.
	Cell Cycle Analysis
	Cell Line:	LNCaP-LN3 cells
	Concentration:	0.5mM, 2mM
	Incubation Time:	24 hours, 48 hours
	Result:	The S phase ratio of the cells was decreased, while their G1 phase ratio was increased.
	Apoptosis Analysis
	Cell Line:	LNCaP-LN3 cells
	Concentration:	0.5mM
	Incubation Time:	24 hours
	Result:	Increased the apoptotic cells.
	Western Blot Analysis
	Cell Line:	LNCaP-LN3 cells
	Concentration:	2mM
	Incubation Time:	48 hours
	Result:	Induced an increase of cytochrome c and a decrease of caspase-3.
体内研究	Pargyline (10 mg/kg; iv) treatment induces a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats A low dose of Pargyline (200μg; icv) injected directly into the brain lowered arterial pressure. The hypotensive action of Pargylline in SHR appears to be the consequence of Norepinephrine accumulating at an inhibitory α-adrenoceptor in brain.